Literature DB >> 12805056

Labile plasma iron in iron overload: redox activity and susceptibility to chelation.

Breno P Esposito1, William Breuer, Pornpan Sirankapracha, Pensri Pootrakul, Chaim Hershko, Z Ioav Cabantchik.   

Abstract

Plasma non-transferrin-bound-iron (NTBI) is believed to be responsible for catalyzing the formation of reactive radicals in the circulation of iron overloaded subjects, resulting in accumulation of oxidation products. We assessed the redox active component of NTBI in the plasma of healthy and beta-thalassemic patients. The labile plasma iron (LPI) was determined with the fluorogenic dihydrorhodamine 123 by monitoring the generation of reactive radicals prompted by ascorbate but blocked by iron chelators. The assay was LPI specific since it was generated by physiologic concentrations of ascorbate, involved no sample manipulation, and was blocked by iron chelators that bind iron selectively. LPI, essentially absent from sera of healthy individuals, was present in those of beta-thalassemia patients at levels (1-16 microM) that correlated significantly with those of NTBI measured as mobilizer-dependent chelatable iron or desferrioxamine chelatable iron. Oral treatment of patients with deferiprone (L1) raised plasma NTBI due to iron mobilization but did not lead to LPI appearance, indicating that L1-chelated iron in plasma was not redox active. Moreover, oral L1 treatment eliminated LPI in patients. The approach enabled the assessment of LPI susceptibility to in vivo or in vitro chelation and the potential of LPI to cause tissue damage, as found in iron overload conditions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12805056     DOI: 10.1182/blood-2003-03-0807

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  109 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.

Authors:  Yesim Aydinok; Patricia Evans; Chantal Y Manz; John B Porter
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

3.  Non-alcoholic fatty liver disease: is iron relevant?

Authors:  Julia O'Brien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2011-08-12       Impact factor: 6.047

4.  In search of the optimal iron chelation therapy for patients with thalassemia major.

Authors:  Vasilios Berdoukas; John Wood
Journal:  Haematologica       Date:  2011-01       Impact factor: 9.941

5.  A biochemical fluorometric method for assessing the oxidative properties of HDL.

Authors:  Theodoros Kelesidis; Judith S Currier; Diana Huynh; David Meriwether; Christina Charles-Schoeman; Srinivasa T Reddy; Alan M Fogelman; Mohamad Navab; Otto O Yang
Journal:  J Lipid Res       Date:  2011-09-27       Impact factor: 5.922

6.  Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.

Authors:  Louise de Swart; Jan C M Hendriks; Lisa N van der Vorm; Z Ioav Cabantchik; Patricia J Evans; Eldad A Hod; Gary M Brittenham; Yael Furman; Boguslaw Wojczyk; Mirian C H Janssen; John B Porter; Vera E J M Mattijssen; Bart J Biemond; Marius A MacKenzie; Raffaella Origa; Renzo Galanello; Robert C Hider; Dorine W Swinkels
Journal:  Haematologica       Date:  2015-09-18       Impact factor: 9.941

Review 7.  Iron chelation therapy in myelodysplastic syndromes: where do we stand?

Authors:  Mhairi Mitchell; Steven D Gore; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2013-08       Impact factor: 2.929

8.  Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Franklin Hendrick; Erika Friedmann; Maria R Baer; Steven D Gore; Medha Sasane; Carole Paley; Amy J Davidoff
Journal:  J Comp Eff Res       Date:  2015-08       Impact factor: 1.744

Review 9.  The potential adverse effects of haemolysis.

Authors:  Francesca Rapido
Journal:  Blood Transfus       Date:  2017-05       Impact factor: 3.443

Review 10.  Safety of iron fortification and supplementation in malaria-endemic areas.

Authors:  Gary M Brittenham
Journal:  Nestle Nutr Inst Workshop Ser       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.